In an adult patient on the JAK inhibitor baricitinib who has never had chickenpox (varicella) infection, is it necessary or appropriate to administer the recombinant zoster vaccine for shingles prophylaxis?

Recombinant Zoster Vaccine Should Be Given to This Patient—Prior Varicella Infection Is NOT Required

Yes, it is both appropriate and strongly recommended to administer the recombinant zoster vaccine (Shingrix) to this patient on baricitinib, even without prior chickenpox infection. The vaccine is specifically indicated for prevention of herpes zoster (shingles), not primary varicella infection, and does not require previous varicella exposure 1.

Key Understanding: Zoster Vaccine vs. Varicella Vaccine

These are fundamentally different vaccines with different purposes:

• Recombinant zoster vaccine (RZV/Shingrix): A non-live vaccine containing VZV glycoprotein E that prevents shingles. It is not designed to prevent primary chickenpox infection 1.
• Varicella vaccine: A live-attenuated vaccine that prevents primary chickenpox infection—this is what would be contraindicated in immunosuppressed patients.

The FDA label explicitly states that Shingrix is "not indicated for prevention of primary varicella infection (chickenpox)" 1. This is a critical distinction that resolves the apparent confusion in your question.

Why This Patient Needs Zoster Vaccination

For patients on JAK inhibitors like baricitinib, recombinant zoster vaccination is specifically recommended starting at age 18 years and older 2. The most recent 2025 British Society of Gastroenterology guidelines state: "Recombinant zoster vaccination (Shingrix) should be considered in all patients aged 50 or over receiving any immunomodulators or advanced therapies, and patients aged 18 and over starting JAK inhibitors" 2.

The 2022 American College of Rheumatology guidelines similarly recommend recombinant zoster vaccination for RMD patients >18 years of age taking immunosuppressive medication 3.

What About the Lack of Prior Varicella Infection?

This is where clinical practice becomes nuanced:

The patient remains at risk for primary varicella (chickenpox) infection, which the zoster vaccine will not prevent. Current guidelines address this scenario directly:

• If varicella-seronegative and no prior chickenpox history: Consider live varicella vaccination if there is a window of opportunity (≥4 weeks before starting immunosuppression and ≥3 months after stopping) 2, 4.
• If already on baricitinib or unable to stop therapy: Live varicella vaccine is contraindicated. Instead, the patient should be counseled about post-exposure prophylaxis with acyclovir (7-day course starting 7 days after exposure) if exposed to active chickenpox or shingles 2.

The 2024 Taiwan guidelines note that both live zoster vaccine and recombinant zoster vaccine have been shown safe and immunogenic in VZV-seronegative individuals 5. Research confirms that RZV can elicit significant humoral and cellular responses even in VZV-seronegative transplant recipients 6.

Practical Algorithm for This Patient

1. Administer recombinant zoster vaccine (Shingrix) now: Two doses, 2-6 months apart (or 1-2 months apart for high-risk patients) 7, 8. This protects against shingles if the patient later acquires VZV.

2. Assess varicella immunity status: Check history of chickenpox or consider VZV serology 5, 9.

3. If varicella-seronegative:

   • Cannot give live varicella vaccine while on baricitinib (contraindicated in immunosuppressed patients) 2, 4
   • Counsel about exposure avoidance: Avoid contact with active chickenpox or shingles cases
   • Provide post-exposure prophylaxis plan: If exposed, start acyclovir 7 days after exposure for 7 days 2

4. If baricitinib can be safely held: Consider stopping baricitinib for ≥3 months, administering 2 doses of live varicella vaccine (4 weeks apart), then waiting 4 weeks before restarting baricitinib 2, 4. This is often impractical for disease control.

Important Caveats

Breakthrough infections can still occur: Case reports document herpes zoster developing in patients on JAK inhibitors despite completed RZV vaccination 10, 11. JAK inhibitors suppress multiple immunogenic mechanisms that underlie vaccine efficacy. However, vaccination still reduces severity and complications 10.

The recombinant vaccine is non-live and safe: Unlike the old live zoster vaccine (Zostavax), RZV can be administered to immunocompromised patients 12, 8. It does not carry risk of disseminated infection.

Timing considerations: Ideally, administer RZV before starting baricitinib if possible, but if already on therapy, proceed with vaccination—do not delay 2, 3. For rituximab specifically, wait ≥6 months after last dose, but this does not apply to JAK inhibitors 3.

Bottom Line

Administer the recombinant zoster vaccine regardless of prior varicella history. The lack of previous chickenpox does not contraindicate zoster vaccination—it simply means the patient needs additional counseling about primary varicella risk and post-exposure prophylaxis strategies. The zoster vaccine protects against shingles (which could occur if the patient later acquires VZV), while the separate issue of primary varicella prevention requires different management strategies that are largely incompatible with ongoing JAK inhibitor therapy.